Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital

Artelo Biosciences (NASDAQ:ARTL)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $6.00 target price on the stock. D. Boral Capital’s price objective would indicate a potential upside of 460.75% from the stock’s current price.

ARTL has been the topic of a number of other research reports. LADENBURG THALM/SH SH upgraded Artelo Biosciences to a “strong-buy” rating in a research report on Wednesday, December 25th. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Artelo Biosciences in a research note on Monday, December 9th.

Artelo Biosciences Price Performance

Shares of NASDAQ:ARTL opened at $1.07 on Thursday. The company has a market capitalization of $3.46 million, a P/E ratio of -0.37 and a beta of 1.25. The business’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $1.16. Artelo Biosciences has a 1 year low of $0.91 and a 1 year high of $1.70.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.